Assertio Holdings, Inc.
DelistedCIK 1808665fmd_0467WXVT8WZMN6ER6DGXXEV8CQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 230 | 106 | 111 | 156 | 152 | 125 | 119 |
| Cost of revenue | 10 | 20 | 16 | – | – | – | – |
| Gross profit | 220 | 86 | 95 | – | – | – | – |
| Research and development | 10 | 4 | 0 | 0 | 3 | 4 | 2 |
| Selling, general and administrative | 109 | 104 | 53 | 47 | 79 | 75 | 69 |
| Operating income | (194) | (82) | 9 | 39 | (244) | (24) | (22) |
| Interest expense | 58 | 16 | 10 | 8 | 10 | 3 | 3 |
| Interest and investment income | – | – | – | – | 2 | 3 | 3 |
| Other non-operating income (expense) | (28) | 37 | (10) | (8) | (11) | 3 | (8) |
| Income before taxes | (222) | (46) | (1) | 31 | (254) | (22) | (30) |
| Income tax expense | (5) | (17) | 1 | (78) | 78 | 0 | 0 |
| Net income from continuing operations | (217) | (28) | (1) | 110 | (332) | (22) | (30) |
| Net income | (217) | (28) | (1) | 110 | (332) | (22) | (30) |